Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
When asked about each segment of ESG, almost all of the surveyed groups, 94%, said that the impact a pharma has on society is ...
GlobalData on MSN10d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP useLenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Zacks.com on MSN1d
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowGilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback